DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway
- PMID: 36849972
- PMCID: PMC9972622
- DOI: 10.1186/s13018-023-03572-4
DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway
Abstract
The treatment of osteosarcoma (OS) is still mainly surgery combined with systematic chemotherapy, and gene therapy is expected to improve the survival rate of patients. This study aimed to explore the effect of DEP domain 1 protein (DEPDC1) and kinesin super-family protein 4A (KIF4A) in OS and understand its mechanism. Th expression of DEPDC1 and KIF4A in OS cells was detected by RT-PCR and western blot. The viability, proliferation, invasion and migration of OS cells and tube formation of human umbilical vein endothelial cells (HUVECs) after indicated treatment were in turn detected by CCK-8 assay, EdU staining, wound healing assay, transwell assay and tube formation assay. The interaction between DEPDC1 and KIF4A was predicted by STRING and confirmed by co-immunoprecipitation. The expression of epithelial-mesenchymal transition (EMT)-related proteins, tube formation-related proteins and Hippo signaling pathway proteins was detected by western blot. As a result, the expression of DEPDC1 and KIF4A was all increased in U2OS cells. Down-regulation of DEPDC1 suppressed the viability, proliferation, invasion and migration of U2OS cells and tube formation of HUVECs, accompanied by the increased expression of E-cadherin and decreased expression of N-cadherin, Vimentin and VEGF. DEPDC1 was confirmed to be interacted with KIF4A. Upregulation of KIF4A partially reversed the effect of DEPDC1 interference on the above biological behaviors of U2OS cells. Down-regulation of DEPDC1 promoted the expression of p-LATS1 and p-YAP in Hippo signaling pathway, which was reversed by upregulation of KIF4A. In conclusion, down-regulation of DEPDC1 inhibited the malignant biological behavior of OS cells through the activation of Hippo signaling pathway, which could be reversed by upregulation of KIF4A.
Keywords: DEPDC1; Hippo signaling pathway; KIF4A; Osteosarcoma cells.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
Roles of DEPDC1 in various types of cancer (Review).Oncol Lett. 2024 Aug 29;28(5):518. doi: 10.3892/ol.2024.14651. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39296974 Free PMC article. Review.
-
[Downregulation of Herg1 suppresses osteosarcoma proliferation and invasion by targeting Hippo signaling pathway].Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):338-345. doi: 10.3760/cma.j.issn.0253-3766.2019.05.004. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31137166 Chinese.
-
DEP Domain Containing 1 Promotes Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Colorectal Cancer by Enhancing Expression of Suppressor of Zest 12.Cancer Biother Radiopharm. 2021 Feb;36(1):36-44. doi: 10.1089/cbr.2019.3460. Epub 2020 Apr 24. Cancer Biother Radiopharm. 2021. PMID: 32343606
-
Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.Cancer Med. 2023 Jun;12(11):12581-12592. doi: 10.1002/cam4.5932. Epub 2023 Apr 11. Cancer Med. 2023. PMID: 37039264 Free PMC article.
-
KIF4A promotes epithelial-mesenchymal transition by activating the TGF-β/SMAD signaling pathway in glioma cells.Mol Cell Biochem. 2025 Jan;480(1):217-230. doi: 10.1007/s11010-024-04943-z. Epub 2024 Feb 27. Mol Cell Biochem. 2025. PMID: 38411896
Cited by
-
Single cell RNA sequencing reveals endothelial cell killing and resolution pathways in experimental malaria-associated acute respiratory distress syndrome.PLoS Pathog. 2024 Jan 18;20(1):e1011929. doi: 10.1371/journal.ppat.1011929. eCollection 2024 Jan. PLoS Pathog. 2024. PMID: 38236930 Free PMC article.
-
DEPDC1 facilitated malignant phenotypes and disease progression of liposarcoma by modulating KIF20A.Front Endocrinol (Lausanne). 2025 Jun 17;16:1591390. doi: 10.3389/fendo.2025.1591390. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40600015 Free PMC article.
-
Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression.Heliyon. 2024 Feb 29;10(5):e27150. doi: 10.1016/j.heliyon.2024.e27150. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38449652 Free PMC article.
-
Roles of DEPDC1 in various types of cancer (Review).Oncol Lett. 2024 Aug 29;28(5):518. doi: 10.3892/ol.2024.14651. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39296974 Free PMC article. Review.
-
DEPDC1 affects autophagy-dependent glycolysis levels in human osteosarcoma cells by modulating RAS/ERK signaling through TTK.Anticancer Drugs. 2024 Nov 1;35(10):893-901. doi: 10.1097/CAD.0000000000001643. Epub 2024 Jul 15. Anticancer Drugs. 2024. PMID: 39016842 Free PMC article.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87–108. - PubMed
-
- Cepeda M, Sosa AJ, Mora G. Telangiectatic osteosarcoma in an infant. Boletin medico del Hospital Infantil de Mexico. 2017;74:60–64. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J Clin. 2020;70:7–30. - PubMed
-
- Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol: H&O. 2010;8:705–718. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous